Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Children's toxicology from bench to bed--Drug-induced renal injury (1): The toxic effects of ARB/ACEI on fetal kidney development.

Sekine T, Miura K, Takahashi K, Igarashi T.

J Toxicol Sci. 2009;34 Suppl 2:SP245-50. Review.

2.

No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.

Han SW, Won YW, Yi JH, Kim HJ.

Nephrol Dial Transplant. 2007 Apr;22(4):1150-5. Epub 2007 Jan 25.

PMID:
17255126
3.

Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.

Onuigbo MA.

Nephron Clin Pract. 2009;113(2):c63-9, discussion c70. doi: 10.1159/000228536. Epub 2009 Jul 14. Review.

4.

Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker.

Miura K, Sekine T, Iida A, Takahashi K, Igarashi T.

Pediatr Nephrol. 2009 Jun;24(6):1235-8. doi: 10.1007/s00467-008-1091-8. Epub 2009 Jan 20.

PMID:
19153776
5.
7.

Embryogenesis of the congenital anomalies of the kidney and the urinary tract.

Kuwayama F, Miyazaki Y, Ichikawa I.

Nephrol Dial Transplant. 2002;17 Suppl 9:45-7.

PMID:
12386286
8.

How they begin and how they end: classic and new theories for the development and deterioration of congenital anomalies of the kidney and urinary tract, CAKUT.

Pope JC 4th, Brock JW 3rd, Adams MC, Stephens FD, Ichikawa I.

J Am Soc Nephrol. 1999 Sep;10(9):2018-28. Review.

9.

An intact renin-angiotensin system is a prerequisite for normal renal development.

Guron G, Friberg P.

J Hypertens. 2000 Feb;18(2):123-37. Review.

PMID:
10694179
10.

Genetics of congenital anomalies of the kidney and urinary tract.

Song R, Yosypiv IV.

Pediatr Nephrol. 2011 Mar;26(3):353-64. doi: 10.1007/s00467-010-1629-4. Epub 2010 Aug 27. Review.

PMID:
20798957
11.

Renin-angiotensin system blockade and contrast-induced renal toxicity.

Saudan P, Muller H, Feraille E, Martin PY, Mach F.

J Nephrol. 2008 Sep-Oct;21(5):681-5.

PMID:
18949722
13.

Teratogen update: angiotensin-converting enzyme inhibitors.

Barr M Jr.

Teratology. 1994 Dec;50(6):399-409. Review.

14.

Role of angiotensin in the development of the kidney and urinary tract.

Pope JC 4th, Nishimura H, Ichikawa I.

Nephrologie. 1998;19(7):433-6. Review.

PMID:
9857380
15.
16.
17.

Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.

Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.

Kidney Blood Press Res. 2009;32(4):268-75. doi: 10.1159/000239765. Epub 2009 Sep 18.

18.

Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers.

Spaggiari E, Heidet L, Grange G, Guimiot F, Dreux S, Delezoide AL; Renin-Angiotensin System Blockers Study Group, Muller F.

Prenat Diagn. 2012 Nov;32(11):1071-6. doi: 10.1002/pd.3960. Epub 2012 Aug 18.

PMID:
22903358
19.
20.

Effect of drugs on renal development.

Schreuder MF, Bueters RR, Huigen MC, Russel FG, Masereeuw R, van den Heuvel LP.

Clin J Am Soc Nephrol. 2011 Jan;6(1):212-7. doi: 10.2215/CJN.04740510. Epub 2010 Nov 11. Review.

Supplemental Content

Support Center